Sivik Global Healthcare LLC Has $8.80 Million Stake in Boston Scientific Co. (NYSE:BSX)

Sivik Global Healthcare LLC trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX) by 8.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 105,000 shares of the medical equipment provider’s stock after selling 10,000 shares during the quarter. Boston Scientific makes up 3.7% of Sivik Global Healthcare LLC’s portfolio, making the stock its 8th biggest position. Sivik Global Healthcare LLC’s holdings in Boston Scientific were worth $8,799,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in BSX. Metis Global Partners LLC raised its position in shares of Boston Scientific by 3.9% during the 3rd quarter. Metis Global Partners LLC now owns 59,226 shares of the medical equipment provider’s stock valued at $4,963,000 after acquiring an additional 2,248 shares in the last quarter. Aubrey Capital Management Ltd lifted its position in shares of Boston Scientific by 3.4% in the 3rd quarter. Aubrey Capital Management Ltd now owns 49,200 shares of the medical equipment provider’s stock worth $4,123,000 after buying an additional 1,600 shares during the last quarter. KBC Group NV boosted its holdings in shares of Boston Scientific by 24.3% in the 3rd quarter. KBC Group NV now owns 2,338,801 shares of the medical equipment provider’s stock valued at $195,991,000 after buying an additional 457,383 shares during the period. Huntington National Bank grew its position in shares of Boston Scientific by 7.6% during the 3rd quarter. Huntington National Bank now owns 1,198,556 shares of the medical equipment provider’s stock valued at $100,439,000 after buying an additional 84,830 shares during the last quarter. Finally, Bouvel Investment Partners LLC grew its position in shares of Boston Scientific by 1.6% during the 3rd quarter. Bouvel Investment Partners LLC now owns 45,148 shares of the medical equipment provider’s stock valued at $3,783,000 after buying an additional 702 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares in the company, valued at $133,046,484.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of Boston Scientific stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the sale, the executive vice president now owns 160,467 shares of the company’s stock, valued at approximately $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 309,270 shares of company stock valued at $26,196,718. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BSX. Stifel Nicolaus lifted their target price on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Bank of America boosted their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Morgan Stanley increased their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. Barclays boosted their price target on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, August 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $93.39.

Boston Scientific Trading Down 0.6 %

Boston Scientific stock opened at $88.28 on Thursday. Boston Scientific Co. has a 52 week low of $53.56 and a 52 week high of $89.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The firm has a market capitalization of $130.11 billion, a price-to-earnings ratio of 73.36, a P/E/G ratio of 2.61 and a beta of 0.79. The company has a 50 day moving average price of $85.03 and a 200 day moving average price of $79.33.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. Boston Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. Research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.